Opinion|Videos|July 11, 2024
Recent findings from BESPOKE
Key opinion leaders analyze recent findings from the BESPOKE study.
Advertisement
Episodes in this series
- BESPOKE Interim analysis: ctDNA for informing ACT in stage II/III CRC (
Kasi, et al. ASCO GI 2024. Abstract 9. )
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
5